---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-062154"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:53:33.074855+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion presents COVALENT-111 data: up to 1.4% placebo-adjusted HbA1c reduction at Week 26 off therapy

## Summary
- Placebo-adjusted mean HbA1c reduction up to 1.4% at Week 26 after 28-day BMF-219 treatment.
- 100mg and 200mg dose levels selected for expansion phase; 12-week dosing, follow-up to Week 52.
- No serious adverse events or study discontinuations; no symptomatic hypoglycemia.
- Expansion phase enrolling on schedule; initial 26-week data expected 2H24.
- Biomea plans to announce COVALENT-112 T1D update in Q4 2023 earnings release.

## SEC filing metadata
- accession: 0001193125-24-062154
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312524062154/0001193125-24-062154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312524062154/d802391d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-062154
- JSON: https://secwatch.observer/filing/0001193125-24-062154.json
- Plain text: https://secwatch.observer/filing/0001193125-24-062154.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.